Historique
Article de Périodique
Buprenorphine and naloxone interactions in methadone maintenance patients (1997)
(Interactions entre la buprenorphine et la naloxone chez les patients sous méthadone)
Auteur(s) :
MENDELSON, J. ;
JONES, R. T. ;
WELM, S. ;
BROWN, J. ;
BATKI, S. L.
Année :
1997
Page(s) :
1095-1101
Langue(s) :
Anglais
Refs biblio. :
24
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
BUPRENORPHINE
;
INTERACTION CHIMIQUE
;
NALOXONE
;
METHADONE
;
ANTAGONISTE
;
VOIE INTRAVEINEUSE
;
SYNDROME DE SEVRAGE
Note générale :
Biological Psychiatry, 1997, 41, (11), 1095-1101
Résumé :
FRANÇAIS :
Les toxicomanes s'injectent parfois abusivement la buprénorphine sublinguale qui leur est prescrite. L'étude réalisée sur 6 patients sous méthadone décrit les effets physiologiques et les effets subjectifs de l'injection IV de buprénorphine, de naloxone et de l'association buprénorphine-naloxone. La buprénorphine n'a pas d'effets physiologiques et subjectifs, la naloxone entraîne des symptômes de sevrage prononcés. L'association des deux médicaments provoque les symptômes caractéristiques des antagonistes des opiacés. [Résumé Toxibase]
ENGLISH:
Buprenorphine is undergoing clinical trials for the treatment of opiate addiction. Although the abuse liability of sublingual buprenorphine is low, reports of intravenous abuse have appeared. This study describes the physiologic and subjective effects of intravenously administered buprenorphine and naloxone given alone and in combination to methadonemaintained patients (40-60 mg/day). On four separate occasions at least 1 day apart, 6 subjects were administered either 0.2 mg buprenorphine, 0.1 mg naloxone, 0.2 mg buprenorphine and 0.1 mg naloxone in combination, or placebo. One male subject quit the experiment after three sessions because of excessive opiate withdrawal. Buprenorphine produced no significant physiologic or subjective effects. Naloxone produced marked opiate withdrawal symptoms. Buprenorphine in combination with naloxone produced characteristic physiologic and subjective opiate antagonist-like symptoms and signs. The parenteral abuse potential of the buprenorphine and naloxone combination is discussed.
Les toxicomanes s'injectent parfois abusivement la buprénorphine sublinguale qui leur est prescrite. L'étude réalisée sur 6 patients sous méthadone décrit les effets physiologiques et les effets subjectifs de l'injection IV de buprénorphine, de naloxone et de l'association buprénorphine-naloxone. La buprénorphine n'a pas d'effets physiologiques et subjectifs, la naloxone entraîne des symptômes de sevrage prononcés. L'association des deux médicaments provoque les symptômes caractéristiques des antagonistes des opiacés. [Résumé Toxibase]
ENGLISH:
Buprenorphine is undergoing clinical trials for the treatment of opiate addiction. Although the abuse liability of sublingual buprenorphine is low, reports of intravenous abuse have appeared. This study describes the physiologic and subjective effects of intravenously administered buprenorphine and naloxone given alone and in combination to methadonemaintained patients (40-60 mg/day). On four separate occasions at least 1 day apart, 6 subjects were administered either 0.2 mg buprenorphine, 0.1 mg naloxone, 0.2 mg buprenorphine and 0.1 mg naloxone in combination, or placebo. One male subject quit the experiment after three sessions because of excessive opiate withdrawal. Buprenorphine produced no significant physiologic or subjective effects. Naloxone produced marked opiate withdrawal symptoms. Buprenorphine in combination with naloxone produced characteristic physiologic and subjective opiate antagonist-like symptoms and signs. The parenteral abuse potential of the buprenorphine and naloxone combination is discussed.
Affiliation :
Drug Dependence Research Center, Langley Porter Psychiatric Institute,
Department of Psychiatry, University of California, San Francisco, San
Francisco, California, USA
Department of Psychiatry, University of California, San Francisco, San
Francisco, California, USA